MichaelWallaceMeshadMD

PubMed

• 6 citations
  Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
  Brenda P. Nicholson, David M. Paul, Kenneth R. Hande, Yu Shyr, Michael Meshad, Alan Cohen, David H. Johnson> ;Clinical Breast Cancer. 2000 Jul 1
• 16 citations
  Oral Ondansetron 8 mg Twice Daily is as Effective as 8 mg Three Times Daily in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemo...
  Thomas M. Beck, Martin York, A Y Chang, Rudolph M. Navari, Walter H. Harvey, Michael Meshad, Daniel Griffin, Alison Wentz> ;Cancer Investigation. 1997 Jan 1
• 14 citations
  Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
  William R. Berry, Karen W. House, Jeffrey T. Lee, Paige B. Plagge, Michael W. Meshad, Richard Grapski> ;Seminars in Oncology. 1992 Dec 1
• Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU.
  W P Peters, G Weiss, D W Kufe> ;Cancer Chemotherapy and Pharmacology. 1984 Jan 1
• 7 citations
  Chemotherapy for Advanced Carcinoma of the Head and Neck: A Clinical Update
  Thomas J. Ervin, Daniel P. Miller, Ralph R. Weichselbaum, Richard L. Fabian, Michael Meshad> ;Archives of Otolaryngology. 1981 Apr 1
• 7 citations
  Phase I trial of mitoxantrone by 24-hour continuous infusion.
  Kenneth C. Anderson, Marc B. Garnick, Meshad Mw, G. I. Cohen, William J. Pegg, Emil Frei, Mervyn Israel, Edward J. Modest, George P. Canellos> ;Cancer Treatment Reports. 1983 May 1
• Phase I trial of combination therapy with PALA and 5-FU.
  Meshad, M. W., Ervin, T. J., Kufe, D., Johnson, R. K., Blum, R. H., Frei, E.> ;Cancer Treat Rep. 1981 Mar 01
• A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
  Weiss, G. R., Ervin, T. J., Meshad, M. W., Schade, D., Branfman, A. R., Bruni, R. J., Chadwick, M., Kufe, D. W.> ;Cancer Chemother Pharmacol. 1982
• Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
  Weiss, G. R., Ervin, T. J., Meshad, M. W., Kufe, D. W.> ;Cancer Treat Rep. 1982 Feb
• 14 citations
  Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
  Thomas J. Ervin, Ronald H. Blum, Meshad Mw, Donald Kufe, Johnson Rk, George P. Canellos> ;Cancer Treatment Reports. 1980 Oct 1
• In normal young men acute dopaminergic blockade does not impair free water excretion following a standard water load.
  Cohen, M., Dailey, G., Meshad, M., Renick, J., Kreisberg, R.> ;Commun Psychopharmacol. 1980
• Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
  Paul, D. M., Garrett, A. M., Meshad, M., DeVore, R. D., Porter, L. L., Johnson, D. H.> ;Semin Oncol. 1996 Feb
• Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies....
  Cubeddu, L. X., Pendergrass, K., Ryan, T., York, M., Burton, G., Meshad, M., Galvin, D., Ciociola, A. A.> ;Am J Clin Oncol. 1994 Apr
• Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM).
  Ervin, T. J., Weichselbaum, R., Miller, D., Meshad, M., Posner, M., Fabian, R.> ;Cancer Treat Rep. 1981 Sep 01
• Join now to see all